Lactobacillus helveticus (Probiotic Species)
Lactobacillus helveticus is a lactic acid bacterium used to make fermented milks and sold as a probiotic. Its research is strain-specific: each trial tested one named strain or product at its own dose and in its own form (live cells, heat-killed cells or a fermented drink), so a result for one strain cannot be assumed for another. Heat-killed strain MCC1848 improved two positive mood ratings in healthy young adults, and heat-killed GCL1815 gave fewer pooled days with cold-like symptoms in healthy adults, in maker-run trials; a second MCC1848 trial did not repeat the first result. These strains have their own pages. Strain R0052 is studied mostly in two-strain products: with Bifidobacterium longum R0175 for mood, where trials disagree, and as about 5% of Lacidofil, which did not help children with gastroenteritis in a large trial. Milk fermented with strains such as LBK-16H supplies the peptides VPP and IPP; blood pressure results differ between trials. It is not a treatment for any disease.
Benefits
Positive mood ratings with heat-killed strain MCC1848
In 58 healthy young adults, 4 weeks of heat-killed MCC1848 improved two positive mood ratings versus placebo: friendliness on the main mood questionnaire and a feeling-relaxed rating. Negative mood items, anxiety, sleep and fatigue scores did not change, no correction for testing many scores is described, and in a second trial friendliness did not differ. The cells were not alive, so the result cannot be assumed for live strains, and several authors work for the maker.
Upper respiratory symptom days with heat-killed strain GCL1815
In 192 analyzed healthy adults, 6 billion heat-killed GCL1815 cells a day for 8 weeks gave 938 total days with symptoms such as runny nose, fatigue and phlegm versus 1116 on placebo, the main outcome. Days were pooled across people and tested as independent, with no per-person analysis, and chills days were higher (95 versus 51). Four of five authors work for the maker.
Upper respiratory illness duration with strain Lafti L10
In 39 elite athletes over 14 winter weeks, 20 billion CFU of Lafti L10 shortened upper respiratory illness episodes (about 7 versus 11 days) and lowered the number of symptoms versus placebo, but how often and how severely illness occurred did not differ. The strain is sold by Lallemand.
Mood and distress scores with the R0052 and B. longum R0175 pair
In 110 adults with major depression, all also taking antidepressants, the pair lowered questionnaire scores more than placebo over 8 weeks. In 55 healthy volunteers it lowered overall distress scores, but anxiety, perceived stress and urinary cortisol did not differ from placebo. Trials in 79 adults with low mood and 135 healthy adults found no difference. L. helveticus was not tested alone; the pair has its own page.
Stool consistency with heat-treated CP790 fermented milk
In 120 healthy adults prone to constipation, a 100 mL daily drink of milk fermented by CP790 alone and then heat-treated improved stool form, straining and abdominal symptom scores versus acidified milk over 4 weeks. The main outcome was a shift in stool bacteria. The drink held no live bacteria, and the maker funded the trial.
Bowel habits with R0052 as a minor part of the Lacidofil blend
Lacidofil blends L. rhamnosus R0011 with R0052 at about 95 to 5. In 160 healthy adults on an antibiotic, the same pair did not change stool consistency or frequency, the main outcomes, and in 886 young children with gastroenteritis Lacidofil did not help. These results belong to the blend; see the Lacidofil page.
Blood pressure with LBK-16H fermented milk and its peptides
This is research on a fermented milk food, not on the bacteria as a supplement: the effect is attributed to the casein peptides VPP and IPP. In 94 adults with untreated high blood pressure, 300 mL a day for 10 weeks gave 24-hour systolic pressure about 4 mmHg lower than control. A Danish trial and a crossover trial found no significant difference.
Mechanism of action
Strain-specific contact with immune cells
In the GCL1815 cold trial, activation markers on dendritic cells, immune cells that help respond to viruses, were higher than with placebo at 8 weeks on one kind of cell and only trended higher (p = 0.074) on the other. This was shown for one strain only, and a blood marker is not the same as fewer colds.
Peptides made while fermenting milk
When certain strains ferment milk, they cut the milk protein casein into short peptides, including VPP and IPP, which block the ACE enzyme in the test tube. Whether this explains blood pressure changes in people is not established; the lactotripeptides page covers that research.
Gut-brain signaling (proposed)
In the depression trial of R0052 with R0175, the kynurenine to tryptophan ratio fell versus placebo only after statistical adjustment, and a later analysis of the same trial found higher blood BDNF, a nerve growth factor. These are secondary markers from a single trial.
Shifts in gut bacteria and their products
Heat-treated CP790 fermented milk lowered Desulfobacterota bacteria in stool, which tracked with better stool consistency. In a small trial in dancers, R0052 with R0175 shifted stool metabolites without improving gut symptoms.
Clinical trials
Randomized, double-blind, three-arm trial in adults with major depressive disorder, all also taking an antidepressant (fluoxetine, citalopram, amitriptyline or sertraline), comparing L. helveticus R0052 with B. longum R0175 (10 billion CFU in one daily sachet, products supplied by Lallemand), a galactooligosaccharide prebiotic and placebo; the primary outcome was the Beck Depression Inventory (BDI), and dose, strain and medication details come from a later analysis of the same trial (Kazemi et al. 2019, Clin Nutr)
110 adult outpatients in Iran; 81 completed (28 probiotic, 27 prebiotic, 26 placebo).
The BDI score fell from 17.4 to 9.1 with the two-strain product, 18.2 to 15.6 with placebo and 19.7 to 14.1 with the prebiotic (p = 0.042). The kynurenine to tryptophan ratio did not differ between groups unless adjusted for isoleucine. About a quarter of those randomized did not finish. L. helveticus was not tested alone.
Randomized, placebo-controlled trial (NCT04823533) of L. helveticus R0052 with B. longum R0175 (3 billion CFU), products supplied by Rosell-Lallemand; outcomes were wellbeing, quality of life, emotional regulation, anxiety, mindfulness and interoceptive awareness (Morales-Torres et al. 2023, Nutrients)
135 healthy adults in Chile.
No significant effect of the two-strain product on any outcome across the whole group. In an exploratory model, people with high healthy-lifestyle scores who took the product did better on some outcomes; this subgroup finding needs confirmation.
Randomized, double-blind, placebo-controlled trial of heat-killed L. helveticus MCC1848 powder, with POMS 2 mood scores as the primary outcome (Mutoh et al. 2023, Benef Microbes)
58 healthy young adults in Japan.
Two positive mood ratings, friendliness and feeling relaxed, improved versus placebo. Negative mood items (such as anger, nervousness and confusion), STAI anxiety, insomnia and fatigue scores did not differ. No adverse effects. The cells were not alive, and several authors work for Morinaga Milk Industry, which makes the ingredient.
Randomized, double-blind, placebo-controlled trial of capsules containing 6 billion heat-sterilized L. helveticus GCL1815 cells, taken once daily for 8 weeks; the primary endpoint was a daily cold-symptom questionnaire, compared as pooled person-days with a chi-squared test rather than per person; the study had no external funding (Wada et al. 2024, Nutrients)
200 healthy adults in Japan.
Among the 192 people in the efficacy analysis, cumulative days with cold-like symptoms such as feverishness, fatigue, runny nose, nasal congestion and phlegm were 938 with GCL1815 versus 1116 with placebo, a significant difference. An activation marker (HLA-DR) on plasmacytoid dendritic cells rose more than with placebo at 4 and 8 weeks. The cells were heat-killed, four of the five authors are employees of Ezaki Glico, the strain's maker, and no independent repeat is cited here.
10-week randomized, double-blind, placebo-controlled trial of L. helveticus R0052 with L. rhamnosus R0011, the strain pair sold as Lacidofil (8 billion CFU a day), taken with a 1-week course of amoxicillin-clavulanate and for 1 week after (Evans et al. 2016, Br J Nutr)
160 healthy adults (80 probiotic, 80 placebo).
Stool consistency and frequency, the primary outcomes, did not differ from placebo, nor did diarrhea-like episodes, symptom scores or safety measures. A post hoc analysis found diarrhea-like episodes lasted 2.7 versus 3.7 days (P = 0.037). Two authors are from Lallemand Health Solutions.
Randomized, double-blind, placebo-controlled trial (NCT01853124); R0011 with R0052 at 4 billion CFU twice daily for 5 days, registered as Lacidofil (Freedman et al. 2018, N Engl J Med)
886 children aged 3 to 48 months at six Canadian pediatric emergency departments; per the registry, R0052 made up 5% of each sachet.
Moderate-to-severe gastroenteritis within 14 days: 26.1% on probiotic vs 24.7% on placebo (P=0.72). Diarrhea and vomiting duration, unscheduled visits and adverse events did not differ. Funded by CIHR and others; Institut Rosell Lallemand is a registered collaborator.
Randomized, double-blind, placebo-controlled trial of a 100 mL daily drink made with milk fermented by L. helveticus CP790 alone and then heat-treated, against nonfermented milk flavored with lactic acid; the primary outcome was the change in stool bacteria, bowel habits and mood were secondary outcomes, and total mood disturbance and depression-dejection scores on POMS 2 were better than placebo; funded by Asahi Group Holdings (Tanihiro et al. 2024, Nutrients)
120 healthy Japanese adults aged 20 to 59 with a tendency toward constipation (60 per group).
Desulfobacterota bacteria in stool fell versus placebo. Stool form (Bristol scale, p = 0.023), straining (p = 0.042) and abdominal symptom scores (p = 0.043) improved versus placebo, while rectal and stool symptom scores did not differ. The drink contained no live bacteria, and six of the seven authors work for an Asahi Group company.
Randomized, double-blind, placebo-controlled parallel trial of milk fermented with L. helveticus LBK-16H containing the tripeptides IPP and VPP, 150 mL twice daily, measured by 24-hour ambulatory monitoring (Jauhiainen et al. 2005, Am J Hypertens)
94 adults with hypertension not on drug treatment, after a 4-week run-in.
24-hour systolic pressure was 4.1 mmHg and diastolic 1.8 mmHg lower than with the control product (P = .001 and P = .048), with no difference in adverse events.
Randomized, double-blind, placebo-controlled trial of L. helveticus Lafti L10 (Lallemand Health Solutions), 20 billion CFU, over 14 winter weeks (Michalickova et al. 2016, Appl Physiol Nutr Metab)
39 elite athletes in Serbia (20 probiotic, 19 placebo).
Upper respiratory illness episodes were shorter with Lafti L10 (7.25 versus 10.64 days, p = 0.047) and had fewer symptoms (p = 0.035), but illness severity and incidence did not differ from placebo. Most immune blood measures did not change.
Randomized, double-blind, placebo-controlled three-arm trial of 150 or 300 mL a day of L. helveticus fermented milk versus chemically acidified milk, with repeated 24-hour ambulatory blood pressure as the primary outcome (Usinger et al. 2010, J Hum Hypertens)
94 adults in Denmark with prehypertension or borderline hypertension.
24-hour blood pressure did not differ between groups (systolic P = 0.9, diastolic P = 0.2), and heart rate and lipids were unchanged.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Lactobacillus helveticus (Probiotic Species)
Does a study on one L. helveticus strain apply to every L. helveticus product?
No. Each trial tested one named strain or product, often with a partner species, at its own dose and in its own form. Heat-killed MCC1848 was studied for mood, heat-killed GCL1815 and live Lafti L10 for cold-like symptoms, CP790 fermented milk for bowel habits, LBK-16H fermented milk for blood pressure, and R0052 mostly inside two-strain products (tested alone, it did not improve cold and flu days in students). Check that a product names the strain behind the result you care about.
Is this the same as Cerebiome or Lacidofil?
No. Cerebiome pairs L. helveticus R0052 with Bifidobacterium longum R0175, and Lacidofil blends L. rhamnosus R0011 with R0052 at about 95 to 5; each product has its own page. Trials of these products cannot say how much of any effect comes from L. helveticus, because it was not tested alone in them. This page covers the species and its other studied strains.
Can a heat-killed product work like a live probiotic?
They are studied separately. Heat-killed MCC1848 powder, heat-killed GCL1815 capsules and heat-treated CP790 fermented milk contain no live bacteria, so researchers sometimes call them postbiotics and CFU counts do not apply. Their maker-run trials do not tell you what a live strain will do, or the other way round.
Will fermented milk made with L. helveticus lower my blood pressure?
Trials disagree. A Finnish trial of LBK-16H fermented milk found 24-hour systolic pressure about 4 mmHg lower than control, but a Danish trial using 24-hour readings and a Finnish crossover trial found no significant difference in its combined analysis. The effect is attributed to the milk peptides VPP and IPP, covered on the lactotripeptides page. It is not a substitute for blood pressure treatment.
What is Lactobacillus helveticus?
Lactobacillus helveticus is a lactic acid bacterium used to make fermented milks and sold as a probiotic. Its research is strain-specific: each trial tested one named strain or product at its own dose and in its own form (live cells, heat-killed cells or a fermented drink), so a result for one strain cannot be assumed…
What is Lactobacillus helveticus used for?
NutraSmarts does not list Lactobacillus helveticus under a health category. What the research covers: In 58 healthy young adults, 4 weeks of heat-killed MCC1848 improved two positive mood ratings versus placebo: friendliness on the main mood questionnaire and a feeling-relaxed rating.
What is the recommended dosage of Lactobacillus helveticus?
The clinically studied dose is 6 billion heat-killed cells/day of GCL1815; heat-killed MCC1848 powder daily for 4 weeks; 20 billion CFU of Lafti L10; 3 to 10 billion CFU/day of R0052 with B. longum R0175; 8 billion CFU/day of R0011 with R0052; 100 to 300 mL/day of fermented milk. Always follow the product label and check with a healthcare provider for personal advice.
Is Lactobacillus helveticus safe, and does it have side effects?
Side effects and cautions reported for Lactobacillus helveticus include: In the cited trials that reported side effects, rates were similar with the active product and placebo. In 886 young children given R0011 with R0052, adverse events occurred in 34.8% on the probiotic and 38.7% on placebo. It may also interact with some medications. Lactobacillus helveticus is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Lactobacillus helveticus interact with any medications?
Possible interactions include: Antibiotics: in the antibiotic trial cited here the probiotic was taken alongside amoxicillin-clavulanate and did not change the main stool outcomes; ask a pharmacist how to time a live probiotic around antibiotic doses. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Lactobacillus helveticus?
NutraSmarts rates the evidence for Lactobacillus helveticus as Limited (2 out of 5). It is backed by 10 study summaries and 17 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(17 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019;38(2):522-528. doi: 10.1016/j.clnu.2018.04.010.PubMedUsed to support: Double-blind trial in Iran: 110 adults with major depression were randomized to L. helveticus with B. longum, a prebiotic (galactooligosaccharide) or placebo for 8 weeks alongside their antidepressants (per a later analysis of the same trial), and 81 finished. The Beck Depression Inventory score fell from 17.4 to 9.1 with the probiotic versus 18.2 to 15.6 with placebo (p = 0.042); the prebiotic had no significant effect. The kynurenine to tryptophan ratio did not differ between groups unless adjusted for serum isoleucine.
- Effects of a Psychobiotic Supplement on Serum Brain-derived Neurotrophic Factor Levels in Depressive Patients: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2020;26(4):486-495. doi: 10.5056/jnm20079.PubMedUsed to support: Exploratory post hoc analysis of the same Iranian depression trial (78 of the 110 participants). Its methods state that the product was L. helveticus R0052 with B. longum R0175 (Cerebiome), 10 billion CFU in one sachet a day for 8 weeks, supplied by Lallemand Health Solutions; all participants were also taking an antidepressant (fluoxetine, citalopram, amitriptyline or sertraline). Blood BDNF, a nerve growth factor, rose more with the probiotic than with placebo (P = 0.021). It re-analyzes one trial and is not an independent confirmation.
- A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust N Z J Psychiatry. 2017;51(8):810-821. doi: 10.1177/0004867416686694.PubMedUsed to support: Double-blind trial in New Zealand of 79 adults with at least moderate low mood who were not taking psychiatric medicines. The full text names the product as Lallemand's R0052 with B. longum R0175 at 3 billion CFU a day. After 8 weeks there was no difference from placebo on any mood measure or blood marker; 23% versus 26% were responders. The lead author had received research funding from Lallemand.
- Psychobiotic Effects on Anxiety Are Modulated by Lifestyle Behaviors: A Randomized Placebo-Controlled Trial on Healthy Adults. Nutrients. 2023;15(7):1706. doi: 10.3390/nu15071706.PubMedUsed to support: Placebo-controlled trial of 135 healthy adults given L. helveticus R0052 with B. longum R0175 (3 billion CFU, per the full text) for 4 weeks. There was no significant effect on wellbeing, quality of life, emotional regulation, anxiety, mindfulness or body awareness in the whole group. An exploratory model linked benefits to people with healthier lifestyles. Rosell-Lallemand supplied the products; the authors report no financial tie to it.
- Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105(5):755-64. doi: 10.1017/S0007114510004319.PubMedUsed to support: Rat experiment plus a 30-day double-blind, placebo-controlled trial in 55 healthy volunteers taking R0052 with B. longum R0175 (3 billion CFU a day). An overall distress index and its somatization, depression and anger-hostility subscales, and the HADS total score, improved more than placebo. The HADS anxiety subscale (P = 0.06), perceived stress and 24-hour urinary free cortisol did not differ between groups. The maker funded the trial.
- Heat-killed Lactobacillus helveticus improves mood states: a randomised, double-blind, placebo-controlled study. Benef Microbes. 2023;14(2):109-118. doi: 10.3920/BM2022.0048.PubMedUsed to support: Randomized, double-blind trial in 58 healthy young adults in Japan: 4 weeks of heat-killed L. helveticus MCC1848 improved two positive mood ratings (friendliness on POMS 2 and a relaxed rating) versus placebo, with no effect on negative mood items, anxiety (STAI), sleep or fatigue scores, and no adverse effects. Several authors work for Morinaga Milk Industry.
- Lactobacillus helveticus Induces Two Types of Dendritic Cell Activation and Effectively Suppresses Onset of the Common Cold: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024;17(1):101. doi: 10.3390/nu17010101.PubMedUsed to support: Randomized, double-blind trial in 200 healthy adults in Japan: capsules with 6 billion heat-sterilized L. helveticus GCL1815 cells (per the full text), once daily for 8 weeks, lowered the cumulative days with cold symptoms such as feverishness, fatigue, runny nose, nasal congestion and phlegm versus placebo, and raised activation markers on two kinds of dendritic cells. Four of the five authors are employees of Ezaki Glico, which makes the strain.
- Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. Appl Physiol Nutr Metab. 2016;41(7):782-9. doi: 10.1139/apnm-2015-0541.PubMedUsed to support: Randomized, double-blind trial in 39 elite athletes in Serbia over 14 winter weeks: L. helveticus Lafti L10 (Lallemand), 20 billion CFU, shortened upper respiratory illness episodes (7.3 versus 10.6 days, p = 0.047) and reduced the number of symptoms, but the incidence and severity of illness did not differ from placebo, and most immune blood measures did not change.
- Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2016;116(1):94-103. doi: 10.1017/S0007114516001665.PubMedUsed to support: Randomized, double-blind trial in 160 healthy adults given a week of amoxicillin-clavulanate plus L. helveticus R0052 with L. rhamnosus R0011 (8 billion CFU a day) or placebo, continued for a week after the antibiotic. The primary outcomes, stool consistency and frequency, did not differ from placebo, nor did symptom scores. A post hoc analysis found diarrhea-like episodes lasted 2.7 versus 3.7 days. Two authors are from Lallemand Health Solutions.
- Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis. N Engl J Med. 2018;379(21):2015-2026. doi: 10.1056/NEJMoa1802597.PubMedUsed to support: Randomized, double-blind trial at six Canadian pediatric emergency departments in 886 children aged 3 to 48 months with gastroenteritis: L. rhamnosus R0011 and L. helveticus R0052, 4 billion CFU twice daily for 5 days, did not reduce moderate-to-severe gastroenteritis within 14 days (26.1% vs 24.7%, P=0.72). Diarrhea duration (52.5 vs 55.5 hours), vomiting duration, unscheduled visits and adverse events (34.8% vs 38.7%) did not differ. Funded by the Canadian Institutes of Health Research and others. The trial registry (NCT01853124) names the product Lacidofil (95% R0011, 5% R0052) and lists Institut Rosell Lallemand as an industry collaborator.
- Effects of Heat-Treated Lactobacillus helveticus CP790-Fermented Milk on Gastrointestinal Health in Healthy Adults: A Randomized Double-Blind Placebo-Controlled Trial. Nutrients. 2024;16(14):2191. doi: 10.3390/nu16142191.PubMedUsed to support: Randomized, double-blind trial in 120 healthy Japanese adults aged 20 to 59 who tended toward constipation: 100 mL a day of a drink made with heat-treated milk fermented by L. helveticus CP790, for 4 weeks, improved stool consistency and straining versus an acidified-milk placebo, lowered Desulfobacterota bacteria in stool, and improved total mood disturbance scores. Six of the seven authors work for an Asahi Group company.
- A Randomized Controlled Trial Evaluating the Effects of a Probiotic Containing Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on Gastrointestinal Symptoms and Metabolomic Profiles in Female Dancers. Int J Mol Sci. 2025;26(12):5823. doi: 10.3390/ijms26125823.PubMedUsed to support: Randomized 12-week trial in female dancers of R0052 with B. longum R0175 (3 billion CFU a day): only 16 women were analyzed (5 probiotic, 11 placebo). The stool metabolite profile shifted, but gastrointestinal symptoms did not improve. No adverse events occurred. Some authors have ties to a probiotic company.
- Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens. 2005;18(12 Pt 1):1600-5. doi: 10.1016/j.amjhyper.2005.06.006.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 94 adults with untreated hypertension: 150 mL twice a day of milk fermented with L. helveticus LBK-16H, rich in the peptides IPP and VPP, for 10 weeks gave 24-hour systolic pressure 4.1 mmHg and diastolic 1.8 mmHg lower than a control product. Adverse events did not differ.
- The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. J Hum Hypertens. 2010;24(10):678-83. doi: 10.1038/jhh.2010.4.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in Denmark of 94 adults with high-normal or borderline blood pressure: 150 or 300 mL a day of L. helveticus fermented milk for 8 weeks did not change 24-hour blood pressure versus acidified milk (systolic P = 0.9, diastolic P = 0.2). The authors concluded the fermented milk had no significant blood pressure effect.
- Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens. 2004;18(11):795-802. doi: 10.1038/sj.jhh.1001745.PubMedUsed to support: Two-period crossover trial in Finland starting with 60 adults with untreated mild hypertension: 150 mL a day of L. helveticus sour milk with about 5 mg of IPP plus VPP versus regular sour milk. Results differed between the two periods, and in the combined analysis the extra systolic drop of 2.6 mmHg and diastolic drop of 1.0 mmHg were not statistically significant.
- Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial (PROGUT, NCT01853124), study record. ClinicalTrials.gov. 2026;Registry record NCT01853124, accessed 2026..SourceUsed to support: Trial registry record, not PubMed-indexed, read in 2026. It names the study product Lacidofil: one sachet twice daily for 5 days, each with at least 4 billion CFU of L. rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%), against a maltodextrin placebo. It lists Institut Rosell Lallemand as an industry collaborator alongside the Canadian Institutes of Health Research.
- Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4.PubMedUsed to support: Cited here for safety only; it pooled many probiotic strains in children taking antibiotics and is not a study of L. helveticus. No serious adverse events were seen in otherwise healthy children, but the authors report serious adverse events in severely debilitated or immunocompromised children with risk factors such as central venous catheter use, and advise avoiding probiotics in groups at risk.